Colgate-Palmolive Company (NYSE: CL) has faced a challenging stretch. The stock trades near $78/share, down about 23% over the past year as cost pressures, foreign exchange headwinds, and slowing volumes weighed on sentiment. Despite this, Colgate remains one of the most dependable names in consumer staples, supported by resilient global demand and strong cash flow generation.
Recently, the company reported steady second-quarter results, driven by price increases across key categories and double-digit growth in its Hill’s Pet Nutrition segment. Management also launched new premium oral care lines and expanded its Colgate Naturals portfolio in emerging markets, reflecting efforts to protect margins and capture share in higher-value products. These moves highlight Colgate’s continued push for innovation and category leadership even in a slow-growth environment.
This article explores where Wall Street analysts think Colgate-Palmolive could trade by 2027. We’ve compiled consensus forecasts and TIKR’s Guided Valuation Model to map out the stock’s potential path. These figures reflect current analyst expectations and not TIKR’s own predictions.
Unlock our Free Report: 5 AI compounders that analysts believe are undervalued and could deliver years of outperformance with accelerating AI adoption (Sign up for TIKR, it’s free) >>>
Analyst Price Targets Suggest Modest Upside
Colgate-Palmolive trades at about $78/share today. The average analyst price target is $92/share, which points to roughly 18% upside. Forecasts remain tight, showing balanced but cautious sentiment among analysts:
● High estimate: ~$105/share
● Low estimate: ~$82/share
● Median target: ~$92/share
● Ratings: 8 Buys, 5 Outperforms, 7 Holds, 1 Underperform, 1 Sell
The modest 18% upside suggests that Wall Street sees Colgate as fairly valued for now. Analysts appear confident in the company’s stability but aren’t expecting major re-rating unless organic growth strengthens or cost savings accelerate.
For investors, Colgate looks like a defensive compounder that can deliver consistent but moderate returns. The stock could outperform if management successfully boosts volumes in emerging markets or expands Hill’s Pet Nutrition faster than expected.
See analysts’ growth forecasts and price targets for Colgate (It’s free!) >>>
Colgate-Palmolive: Growth Outlook and Valuation
The company’s fundamentals appear stable, but not particularly strong:
● Revenue is projected to grow ~2.8% annually through 2027
● Operating margins are expected to stay near ~22%
● Shares trade at ~21× forward earnings, roughly in line with their historical average
● Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a fair multiple suggests ~$94/share by 2027
● That implies about 21% total upside, or roughly 9% annualized returns
These numbers suggest Colgate can compound steadily but without much acceleration. The stock’s valuation looks fair for its growth profile, which means upside depends on sustained margin improvement and continued pricing strength rather than major volume recovery.
For investors, Colgate is more of a defensive brand play than a growth story, offering steady earnings, dependable dividends, and predictable compounding over time.
Value stocks like Colgate in as little as 60 seconds with TIKR (It’s free) >>>
What’s Driving the Optimism?
Colgate’s brand strength and pricing power continue to anchor its long-term story. The company holds dominant market share in oral care and is steadily expanding into higher-margin segments like Hill’s Pet Nutrition, which remains one of its fastest-growing businesses.
Recent innovation and marketing investments are also helping sustain momentum. Management’s emphasis on premium product launches and digital marketing is aimed at improving volume growth and protecting margins, particularly in emerging markets.
For investors, Colgate’s consistent execution, diversified product mix, and cost discipline give confidence that earnings can grow steadily, even if overall category demand stays soft.
Bear Case: Sluggish Growth and Cost Pressure
Despite these strengths, Colgate’s valuation looks full. The stock trades around 21× forward earnings, slightly above its historical average, while revenue growth remains below 3% per year.
Inflation pressures, rising input costs, and foreign exchange headwinds could also limit margin expansion. Meanwhile, competition from private labels and rival global brands continues to chip away at market share in mature regions.
For investors, The risk is that Colgate delivers stable but unspectacular returns. Without stronger organic growth or a surprise in profitability, the current valuation already prices in much of its defensive appeal.
Outlook for 2027: What Could Colgate Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model suggests Colgate-Palmolive could trade near $94/share by 2027. That implies about a 21% total return from current levels, or roughly 9% annualized.
While that outlook points to steady compounding, it already assumes modest improvement in margins and earnings. Upside beyond this would likely require faster growth in emerging markets and sustained strength from Hill’s Pet Nutrition.
For investors, Colgate looks like a reliable long-term hold, offering predictable earnings and dividend growth rather than big capital gains. The story here is stability, not acceleration.
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Click here to sign up for TIKR and get your free copy of TIKR’s 5 AI Compounders report today.